This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...